Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

We have observed 34 EP applications James Dyer has served for within the last five+ years. (We consider all applications which have an EP A1 or A2 publication dated after July 16, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP12720761

CSF-1R INHIBITORS FOR TREATMENT OF BRAIN TUMORS

IPC classification:
A61K 45/06, A61K 31/4439, C07D 417/14, A61P 35/00
Applicant:
Novartis AG
Agent:
James Dyer, Novartis Pharma AG
Status:
PATENT GRANTED
EP12738676

TYROSINE LIGATION PROCESS

IPC classification:
A61K 47/48, A61K 39/02, A61K 39/00, A61P 31/00
Applicant:
Novartis AG
Agent:
James Dyer, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP12783308

HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CYSTIC FIBROSIS

IPC classification:
A61K 31/497, A61K 31/4439, C07D 417/04, C07D 413/04, A61P 11/00
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12784701

3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH

IPC classification:
A61K 31/506, C07D 513/04, C07D 498/10, C07D 487/04, C07D 471/04, C07D 417/14, C07D 413/14, C07D 413/04, A61P 35/00
Applicant:
Novartis AG
Agent:
James Dyer, Novartis Pharma AG
Status:
The patent has been granted
EP13158259

Hydroxamate-based inhibitors of deacetylases b

IPC classification:
C07D 401/06, A61P 35/00, A61K 31/4025, A61K 31/40, C07D 471/04, C07D 413/06, C07D 405/06, C07D 403/06, C07D 207/08
Applicant:
Novartis AG
Agent:
James Dyer, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12783311

N-SUBSTITUTED HETEROCYCLYL CARBOXAMIDES

IPC classification:
A61K 31/497, A61K 31/4439, A61K 31/415, A61P 11/06
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP13717317

OXAZOLIDIN- 2 -ONE COMPOUNDS AND USES THEREOF AS PI3KS INHIBITORS

IPC classification:
A61K 31/5377, C07D 413/14, A61P 35/00
Applicant:
Novartis AG
Agent:
James Dyer, Novartis Pharma AG
Status:
PATENT GRANTED
EP14191369

Pyridine and pyrazine derivative for the treatment of chronic obstructive pulmonary disease

IPC classification:
A61K 31/5377, A61K 31/497, A61K 31/4965, A61K 31/4545, A61K 31/444, A61K 31/4439, A61K 31/443, A61K 31/44, A61P 11/12
Applicant:
Novartis AG
Agent:
James Dyer, Novartis Pharma AG
Status:
PATENT GRANTED
EP13730653

BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1

IPC classification:
A61K 31/551, A61K 31/506, A61K 31/444, A61K 31/4439, C07D 498/08, C07D 491/10, C07D 487/10, C07D 487/04, C07D 471/04, C07D 413/14, C07D 413/10, C07D 405/14, C07D 403/10, C07D 401/14, C07D 401/10, C07D 401/04, A61P 35/00
Applicant:
Novartis AG
Agent:
James Dyer, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP13730652

BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1

IPC classification:
A61K 31/4439, C07D 403/10, C07D 401/14, C07D 401/04, C07D 213/82, A61P 35/00
Applicant:
Novartis AG
Agent:
James Dyer, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP13730655

BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1

IPC classification:
A61K 31/5377, A61K 31/496, A61K 31/444, A61K 31/4439, C07D 417/14, C07D 417/10, C07D 413/14, C07D 409/14, C07D 405/14, C07D 403/10, C07D 401/14, C07D 401/04, A61P 31/00
Applicant:
Novartis AG
Agent:
James Dyer, Novartis Pharma AG
Status:
The patent has been granted
EP13731958

NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS

IPC classification:
C07D 417/14, C07D 417/12, C07D 409/14, C07D 407/14, C07D 403/14, C07D 403/12, C07D 401/14, C07D 401/12, A61P 35/00
Applicant:
Novartis AG
Agent:
James Dyer, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP13771007

DIHYDROPYRROLIDINO-PYRIMIDINES AS KINASE INHIBITORS

IPC classification:
A61K 31/519, C07D 487/04, C07D 207/36, A61P 35/00
Applicant:
Novartis AG
Agent:
James Dyer, Novartis Pharma AG
Status:
PATENT GRANTED
EP13730654

COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1

IPC classification:
A61K 31/505, C07D 407/14, C07D 401/04, C07D 317/60, C07D 277/20, C07D 241/20, C07D 241/12, C07D 239/34, C07D 239/30, C07D 239/26, C07D 233/54, C07D 233/38, C07D 231/12, C07D 213/85, C07D 213/81
Applicant:
Novartis AG
Agent:
James Dyer, Novartis Pharma AG
Status:
The patent has been granted
EP13795980

COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES

IPC classification:
A61K 31/4985, C07D 487/04, A61P 33/06
Applicant:
Novartis AG
Agent:
James Dyer, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP11793365

3-(AMINOARYL)-PYRIDINE COMPOUNDS

IPC classification:
A61P 35/00, A61K 31/44, C07D 213/74
Applicant:
Novartis AG
Agent:
James Dyer, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13802452

METHODS FOR MAKING CONJUGATES FROM DISULFIDE-CONTAINING PROTEINS

IPC classification:
A61K 47/48
Applicant:
Novartis AG
Agent:
James Dyer, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP13795977

COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES

IPC classification:
A61K 31/437, C07D 471/04, A61P 33/06
Applicant:
Novartis AG
Agent:
James Dyer, Novartis AG
Status:
EXAMINATION IN PROGRESS
EP13826625

TRICYCLIC COMPOUNDS FOR INHIBITING THE CFTR CHANNEL

IPC classification:
A61K 31/519, C07D 495/14, C07D 487/14, C07D 487/04, A61P 13/12, A61P 1/12
Applicant:
Novartis AG
Agent:
James Dyer, Novartis Pharma AG
Status:
PATENT GRANTED
EP13826624

TRICYCLIC COMPOUNDS AS CFTR INHIBITORS

IPC classification:
A61K 31/5383, A61K 31/519, C07D 498/14, C07D 487/14, A61P 1/12
Applicant:
Novartis AG
Agent:
James Dyer, Novartis Pharma AG
Status:
The patent has been granted
EP13818112

ARYL-SUBSTITUTED FUSED BICYCLIC PYRIDAZINE COMPOUNDS

IPC classification:
A61K 31/495, C07D 487/04, A61P 35/00
Applicant:
Novartis AG
Agent:
James Dyer, Novartis Pharma AG
Status:
APPLICATION REFUSED
EP14723916

CELL PROLIFERATION INHIBITORS AND CONJUGATES THEREOF

IPC classification:
C07D 249/10, C07D 401/12, C07D 233/64, C07D 405/14, A61P 35/00, A61K 47/48
Applicant:
Novartis AG
Agent:
James Dyer, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP14714134

BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS

IPC classification:
C07D 241/20, C07D 239/42, C07D 405/12, C07D 405/04, C07D 237/20, C07D 403/04, C07D 401/12, C07D 401/04, C07D 233/88, C07D 213/75, C07D 213/74, C07D 413/14, C07D 405/14, C07D 401/14, C07D 403/12
Applicant:
Novartis AG
Agent:
James Dyer, Novartis Pharma AG
Status:
The patent has been granted
EP14720357

COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES

IPC classification:
A61P 33/02, A61K 31/519, C07D 491/107, C07D 487/04, C07D 491/08
Applicant:
Novartis AG
Agent:
James Dyer, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP14716934

3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH

IPC classification:
A61P 35/00, C07D 417/14, C07D 413/04, A61K 31/506, C07D 413/14
Applicant:
Novartis AG
Agent:
James Dyer, Novartis Pharma AG
Status:
The patent has been granted
EP14712785

3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH

IPC classification:
A61P 35/00, A61K 31/506, C07D 417/14, C07D 413/04, C07D 413/14
Applicant:
Novartis AG
Agent:
James Dyer, Novartis Pharma AG
Status:
The patent has been granted
EP14800191

AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS

IPC classification:
A61P 35/00, A61K 31/4418, C07D 241/20, C07D 409/04, C07D 405/04, C07D 403/06, C07D 401/12, C07D 401/06, C07D 401/04, C07D 213/73, C07D 413/14, C07D 405/14
Applicant:
Novartis AG
Agent:
James Dyer, Novartis Pharma AG
Status:
The patent has been granted
EP14815051

METHODS FOR OXIME CONJUGATION TO KETONE-MODIFIED POLYPEPTIDES

IPC classification:
A61K 47/48
Applicant:
Novartis AG
Agent:
James Dyer, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP11757294

TRIAZINE-OXADIAZOLES

IPC classification:
A61P 29/00, A61K 31/53, C07D 498/08, C07D 491/10, C07D 487/04, C07D 451/02, C07D 417/14, C07D 413/14, C07D 413/04
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP14825046

[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS PROTOZOAN PROTEASOME INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASES SUCH AS LEISHMANIASIS

IPC classification:
A61P 33/02, A61K 31/519, C07D 487/04
Applicant:
Novartis AG
Agent:
James Dyer, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15750138

PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE

IPC classification:
A61P 31/04, A61K 31/506, C07D 413/14, C07D 401/14
Applicant:
Novartis AG
Agent:
James Dyer, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15766662

COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS

IPC classification:
A61P 35/00, A61K 31/5377, A61K 31/44, A61K 31/444, A61K 31/4439, C07D 413/12, C07D 411/14, C07D 407/14, C07D 401/10, C07D 401/04, C07D 213/74, C07D 413/14, C07D 401/14
Applicant:
Novartis AG
Agent:
James Dyer, Novartis Pharma AG
Status:
Request for examination was made
EP15820637

TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF

IPC classification:
A61P 35/00, A61K 31/519, C07D 487/04
Applicant:
Novartis AG
Agent:
James Dyer, Novartis Pharma AG
Status:
Request for examination was made
EP17190132

BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS

IPC classification:
C07D 403/12
Applicant:
Novartis AG
Agent:
James Dyer, Novartis Pharma AG
Status:
The application has been published

Please Sign in to use this feature